"Unexplained jaw swelling, even when appearing destructive, may not require surgery on the face, but rather a targeted treatment for an overactive gland in the neck. Correcting the underlying hormonal imbalance is often key to resolving these bone complications."
This striking revelation comes from a recent case series highlighting a rare manifestation of a common endocrine disorder. While surgeons encountered jaw lesions that mimicked aggressive bone growths, the true culprit lay in an overactive parathyroid gland. The study, published in the International Journal of Surgery Case Reports, underscores the critical importance of considering systemic hormonal issues before proceeding with local interventions for complex jaw pathologies. The findings suggest that a simple blood test could preempt unnecessary facial surgeries and lead to more effective treatment strategies for patients presenting with these unusual bone abnormalities.
A series of three perplexing cases from oral surgeons at Mohammed V University in Rabat, Morocco, has shed light on a rare but significant complication of hyperparathyroidism: brown tumors of the jaw. These cases, involving women aged 22 to 60, presented with painless, progressively expanding lesions on their upper jaws between 2022 and 2023. The visual and microscopic evidence initially suggested aggressive bone destructive processes, prompting concerns of malignancy or other significant pathological conditions. However, in each instance, the underlying cause was traced back to an overproduction of parathyroid hormone (PTH), a condition known as hyperparathyroidism, which had gone undiagnosed until the jaw lesions became apparent.
In the most striking of the presented cases, a woman experienced swelling on both sides of her upper jaw. One of the lesions had advanced to the point of breaching the outer layer of the maxillary bone. Microscopic examination revealed a dense infiltration of giant cells, a cellular hallmark often associated with various destructive bone pathologies, including some forms of cancer. Despite the alarming appearance of the jaw tissue, surgical intervention on the face was deemed unnecessary. Instead, the focus shifted to a single, overactive gland in her neck—the parathyroid gland—which was identified as the source of the problem.
The Moroccan researchers detailed these three cases in a retrospective series published online in the International Journal of Surgery Case Reports and featured in its September issue. All three women presented with similar, albeit varying, degrees of painless, expanding jaw lesions. These lesions were ultimately diagnosed as brown tumors, a bone manifestation arising from chronic overexposure to excessive levels of parathyroid hormone. Crucially, in each of these patients, the jaw swelling served as the initial, and often only, outward sign of an underlying hormonal imbalance that had not yet been detected through routine medical screening.
A Hormone Reading Far Above the Normal Range
The diagnostic journey for the patient with bilateral upper jaw lesions was particularly revealing. Advanced 3D dental imaging provided a detailed view of the affected areas, showcasing lesions on both sides of the maxilla. The lesion on the right side was clearly demarcated, while the one on the left was larger, less defined, and had indeed perforated the outer bone layer. The bilateral involvement immediately suggested a systemic cause rather than a localized, tooth-related issue.
A subsequent neck ultrasound identified a significant nodule, measuring 54 by 13 millimeters, on the patient’s left parathyroid gland. This finding was highly suggestive of a parathyroid adenoma, a benign tumor that often leads to the overproduction of parathyroid hormone. Blood tests provided definitive confirmation. The patient’s parathyroid hormone level was an astounding 2,062 pg/mL, exceeding the upper limit of a standard reference range by more than thirtyfold. Her blood calcium level was also significantly elevated at 13.3 mg/dL, well above normal parameters. Furthermore, her alkaline phosphatase, a marker that indicates bone turnover and breakdown, was also found to be elevated, further supporting the presence of significant bone metabolic activity.
The four parathyroid glands, located in the neck, play a crucial role in regulating blood calcium levels, which are vital for numerous bodily functions, including nerve transmission, muscle contraction, and bone health. When one or more of these glands become overactive, they secrete excessive amounts of PTH. This hormonal surge prompts an increase in the activity of osteoclasts, the cells responsible for bone resorption. In essence, the excess hormone signals the body to break down bone tissue to release calcium into the bloodstream. In certain individuals, this prolonged and accelerated bone breakdown can lead to the formation of cavities within the bone. These cavities become filled with fibrous tissue, a characteristic accumulation of giant cells (multinucleated cells involved in bone resorption), and deposits of hemosiderin, the breakdown product of blood pigments. It is this mixture that imparts a brownish hue to the lesions, giving them the name "brown tumors." Despite their potentially alarming appearance and the destructive processes involved, it is imperative to reiterate that brown tumors are benign and not cancerous. The Moroccan authors noted that these tumors typically manifest in the axial skeleton (skull, spine, ribs, pelvis) and that involvement of the jaw, while rare, is a recognized, albeit uncommon, presentation.
Fixing the Neck First
The treatment strategy for this patient prioritized addressing the root cause of the hormonal imbalance. Initially, her dangerously high calcium levels were managed through medical interventions. Once her calcium levels were stabilized, surgeons proceeded with a targeted parathyroidectomy. This procedure involved the precise removal of the diseased parathyroid gland. Crucially, intraoperative hormone level monitoring was employed to ensure that the correct gland had been identified and removed, confirming the success of the intervention. The lesions in her jaw were intentionally left untreated at this stage, a testament to the confidence in the body’s ability to heal once the hormonal derangement was corrected.
A follow-up assessment six months post-surgery revealed significant positive changes. 3D scans demonstrated a noticeable shrinkage of the jaw lesions, and their borders appeared more defined. By the 12-month mark, both upper jaw tumors had regressed markedly, indicating a substantial resolution of the bone abnormalities. Concurrently, her blood levels of calcium, parathyroid hormone, and alkaline phosphatase had all returned to the normal range, signifying a complete biochemical recovery.
The second woman in the series also suffered from primary hyperparathyroidism, presenting with a lesion in her lower jaw. Her parathyroid hormone level was elevated at 914.5 pg/mL. Similar to the first patient, she underwent parathyroid surgery without any intervention on her jaw. Six months later, her lesion had significantly decreased in size. The third patient had a more complex form of the disorder, secondary hyperparathyroidism, which was directly linked to chronic kidney failure and required dialysis. Her case was managed conservatively, focusing on optimizing her dialysis regimen and managing her overall health without direct intervention on the jaw lesion. Importantly, none of the three women required surgery to remove bone from their jaws. This outcome, the authors emphasize, reflects a broader clinical principle: when the underlying hormonal problem is effectively addressed, the brown tumors often regress spontaneously.
This approach is not an isolated observation. A 2023 study conducted in Tunisia, which examined 16 patients with jaw brown tumors, similarly identified parathyroidectomy as the gold-standard treatment for the primary form of the disease. This collective evidence strongly advocates for prioritizing the management of hyperparathyroidism as the primary therapeutic goal.
Easy to Mistake for Something Else
The significant challenge posed by brown tumors lies in their capacity to mimic other, more sinister conditions. On imaging scans and under the microscope, lesions rich in giant cells can bear a striking resemblance to other types of jaw lesions, including giant cell granulomas, aneurysmal bone cysts, and even certain malignant tumors. This diagnostic ambiguity underscores the Moroccan team’s crucial recommendation: whenever jaw lesions appear in multiple locations, are present on both sides of the jaw, or exhibit unusually aggressive behavior, it is imperative to investigate blood calcium and parathyroid hormone levels before planning any local surgical intervention.
A case from Rawalpindi, Pakistan, published in February 2026, vividly illustrates the potential pitfalls of misdiagnosis. In this instance, doctors discovered a large lesion, measuring 5.4 by 4.6 centimeters, in a patient’s right upper jaw. While initial blood tests and nuclear imaging pointed towards a parathyroid adenoma, and subsequent removal of the affected gland led to the resolution of the facial swelling by the two-month follow-up, the authors highlighted that isolated facial swelling can, in fact, be the earliest presenting sign of primary hyperparathyroidism. This case serves as a potent reminder that even seemingly localized facial swelling warrants a thorough systemic evaluation.
A Common Disorder with a Rare Complication
Primary hyperparathyroidism itself is a relatively common endocrine disorder. The National Institute of Diabetes and Digestive and Kidney Diseases estimates that approximately 100,000 individuals in the United States develop this condition annually. It is most frequently diagnosed in individuals between the ages of 50 and 60, with women being affected about three times more often than men.
In contrast, brown tumors are a much rarer complication. They have been reported in approximately 4.5% of individuals diagnosed with primary hyperparathyroidism and in a slightly lower percentage, around 1.5% to 1.7%, of those with the secondary form of the disease. The increasing prevalence of routine blood testing has led to earlier detection of high calcium levels in many individuals, often before significant bone damage, such as brown tumor formation, has occurred. This proactive screening plays a vital role in preventing the development of such complications.
The Moroccan series, while insightful, does have limitations. It comprises only three patients from a single medical center, and its retrospective nature means it relies on reviewing past records. Consequently, it cannot definitively predict how every jaw lesion associated with parathyroid disease will respond to treatment. Furthermore, not all jaw growths linked to hyperparathyroidism behave identically. In a specific inherited condition known as hyperparathyroidism-jaw tumor syndrome, caused by mutations in the CDC73 gene, the jaw growths are typically ossifying fibromas, a distinct type of benign bone lesion.
The overarching practical message derived from these cases and supporting research is clear and actionable. Any unexplained swelling of the jaw or face warrants prompt and thorough evaluation by a dental professional, oral surgeon, or physician. For patients presenting with jaw lesions that are rich in giant cells, a fundamental assessment of calcium and parathyroid hormone levels is a critical step that can fundamentally alter the diagnostic pathway and treatment plan, potentially averting invasive and unnecessary surgical procedures on the face.
Key Questions Answered
What is a brown tumor?
A brown tumor is a benign bone lesion that develops as a consequence of long-term excess parathyroid hormone. Despite its potentially aggressive appearance on imaging and under the microscope, it is not cancerous.
Why did a neck gland affect the jaw?
An overactive parathyroid gland releases excessive parathyroid hormone, which accelerates bone breakdown. In the cases described, this bone destruction manifested most noticeably in the jaw.
Did the patients need jaw surgery?
No. Two patients with primary hyperparathyroidism underwent surgery to remove the overactive parathyroid gland, and their jaw lesions subsequently regressed. The third patient, with secondary hyperparathyroidism, was managed conservatively.
How common are brown tumors?
Brown tumors are relatively uncommon, occurring in about 4.5% of individuals with primary hyperparathyroidism and 1.5% to 1.7% with secondary hyperparathyroidism. Jaw involvement is particularly rare.
What symptoms can hyperparathyroidism cause?
Many individuals with hyperparathyroidism experience no symptoms and are diagnosed incidentally through routine blood tests revealing high calcium levels. Other potential symptoms include kidney stones, bone pain, fatigue, and digestive issues.
What remains uncertain?
The findings from the Moroccan series, based on a small number of patients from a single center, cannot be generalized to predict the outcome for every jaw lesion associated with parathyroid disease. Individual responses to treatment can vary.
